3D Systems has announced a partnership with Klarity to expand the distribution of its VSPBolus solution, which was approved by the US Food and Drug Administration (FDA).
Klarity will add VSP Bolus to its patient-specific 3D-printed products, Klarity Prints, powered by 3D Systems.
Klarity Prints is a service-based line of 3D-printed radiotherapy accessories, including VSP Bolus, which does not need specialised hardware or software.
3D Systems Healthcare Solutions EVP Menno Ellis said: “Klarity has a strong reputation in the radiation oncology sector for delivering superior products and service.
“The company’s commitment to improving patient care through treatment personalisation aligns with 3D Systems’ market-leading service model for delivering high-quality 3D-printed, patient-specific medical devices for over two decades.”
VSP Bolus is intended for the delivery of biocompatible, 3D-printed, patient-specific boluses, which can improve patient comfort, enhance therapy modulation and lower technician time.
Access the most comprehensive company profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – Free
sample
Thank you!
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
The solution is 3D-printed to the exact treatment plan bolus dimensions from a soft, biocompatible material that contours to the anatomy of the patient for an enhanced treatment experience.
Radiotherapy clinics across Canada and the US can now access this 3D-printed solution because of the distribution agreement with Klarity.
Klarity CEO Peter Larson said: “This collaboration aligns perfectly with Klarity’s ongoing commitment to improving the quality of care provided by our customers.
“As a North American distributor of 3D Systems’ 3D-printed biocompatible bolus products, we will be at the forefront of advancing personalised care and improving the patient experience.”